Vera Therapeutics (VERA) Competitors $24.76 +0.52 (+2.15%) Closing price 04:00 PM EasternExtended Trading$24.46 -0.30 (-1.21%) As of 06:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VERA vs. NUVL, TGTX, MRUS, CRSP, PTCT, KRYS, PCVX, ACAD, ACLX, and ADMAShould you be buying Vera Therapeutics stock or one of its competitors? The main competitors of Vera Therapeutics include Nuvalent (NUVL), TG Therapeutics (TGTX), Merus (MRUS), CRISPR Therapeutics (CRSP), PTC Therapeutics (PTCT), Krystal Biotech (KRYS), Vaxcyte (PCVX), ACADIA Pharmaceuticals (ACAD), Arcellx (ACLX), and ADMA Biologics (ADMA). These companies are all part of the "pharmaceutical products" industry. Vera Therapeutics vs. Its Competitors Nuvalent TG Therapeutics Merus CRISPR Therapeutics PTC Therapeutics Krystal Biotech Vaxcyte ACADIA Pharmaceuticals Arcellx ADMA Biologics Nuvalent (NASDAQ:NUVL) and Vera Therapeutics (NASDAQ:VERA) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings. Do insiders & institutionals hold more shares of NUVL or VERA? 97.3% of Nuvalent shares are owned by institutional investors. Comparatively, 99.2% of Vera Therapeutics shares are owned by institutional investors. 10.2% of Nuvalent shares are owned by company insiders. Comparatively, 16.3% of Vera Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Do analysts rate NUVL or VERA? Nuvalent presently has a consensus target price of $119.50, indicating a potential upside of 52.56%. Vera Therapeutics has a consensus target price of $63.00, indicating a potential upside of 154.44%. Given Vera Therapeutics' higher possible upside, analysts clearly believe Vera Therapeutics is more favorable than Nuvalent.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvalent 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09Vera Therapeutics 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78 Which has higher valuation and earnings, NUVL or VERA? Nuvalent is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuvalentN/AN/A-$260.76M-$4.90-15.99Vera TherapeuticsN/AN/A-$152.15M-$3.58-6.92 Is NUVL or VERA more profitable? Nuvalent's return on equity of -32.58% beat Vera Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets NuvalentN/A -32.58% -30.14% Vera Therapeutics N/A -46.70%-39.46% Which has more risk and volatility, NUVL or VERA? Nuvalent has a beta of 1.29, meaning that its stock price is 29% more volatile than the S&P 500. Comparatively, Vera Therapeutics has a beta of 1.17, meaning that its stock price is 17% more volatile than the S&P 500. Does the media prefer NUVL or VERA? In the previous week, Nuvalent had 2 more articles in the media than Vera Therapeutics. MarketBeat recorded 7 mentions for Nuvalent and 5 mentions for Vera Therapeutics. Vera Therapeutics' average media sentiment score of 1.45 beat Nuvalent's score of 1.04 indicating that Vera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvalent 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vera Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryNuvalent and Vera Therapeutics tied by winning 7 of the 14 factors compared between the two stocks. Get Vera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VERA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VERA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VERA vs. The Competition Export to ExcelMetricVera TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.55B$3.12B$5.73B$10.31BDividend YieldN/A2.36%5.90%4.63%P/E Ratio-6.928.1457.1222.76Price / SalesN/A446.35528.74123.58Price / CashN/A45.4037.1760.46Price / Book2.739.6212.796.29Net Income-$152.15M-$53.28M$3.28B$270.51M7 Day Performance-1.28%0.31%0.22%2.15%1 Month Performance14.95%4.58%4.61%6.35%1 Year Performance-38.25%9.24%68.33%25.48% Vera Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VERAVera Therapeutics2.8236 of 5 stars$24.76+2.1%$63.00+154.4%-35.4%$1.55BN/A-6.9240Positive NewsNUVLNuvalent3.1541 of 5 stars$79.83-1.3%$120.91+51.5%-9.2%$5.83BN/A0.0040Positive NewsTGTXTG Therapeutics4.2962 of 5 stars$32.38+0.5%$46.25+42.8%+33.8%$5.11B$329M87.51290Positive NewsMRUSMerus2.7728 of 5 stars$67.19-0.4%$88.75+32.1%+35.8%$5.10B$36.13M-12.2237Positive NewsCRSPCRISPR Therapeutics2.7861 of 5 stars$54.10-1.4%$71.60+32.3%+18.2%$4.99B$37.31M0.00460PTCTPTC Therapeutics3.7221 of 5 stars$56.95-0.5%$69.00+21.2%+73.5%$4.55B$806.78M8.171,410Insider TradeKRYSKrystal Biotech4.9516 of 5 stars$145.20-3.4%$210.38+44.9%-22.8%$4.35B$290.52M30.54210News CoveragePositive NewsAnalyst ForecastPCVXVaxcyte2.1736 of 5 stars$32.41-1.8%$130.00+301.1%-73.3%$4.29BN/A0.00160Positive NewsACADACADIA Pharmaceuticals4.3239 of 5 stars$25.39+0.5%$28.88+13.7%+51.2%$4.26B$957.80M19.09510ACLXArcellx2.1038 of 5 stars$71.11-2.1%$114.31+60.7%-2.2%$4.03B$107.94M0.0080Positive NewsADMAADMA Biologics3.6473 of 5 stars$16.42-2.7%$27.67+68.5%-15.4%$4.03B$426.45M19.09530Positive News Related Companies and Tools Related Companies Nuvalent Competitors TG Therapeutics Competitors Merus Competitors CRISPR Therapeutics Competitors PTC Therapeutics Competitors Krystal Biotech Competitors Vaxcyte Competitors ACADIA Pharmaceuticals Competitors Arcellx Competitors ADMA Biologics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VERA) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredTurn $1K into $50K with This DeFi GemBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredOpenAI’s new $300 billion dealOpenAI just signed a $300 billion cloud deal with Oracle to secure the computing power needed for its next Cha...Porter & Company | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredNew Buy Alert: Should you put $1,000 into Oracle (ORCL) now?Barron's is calling this Oracle's "Nvidia Moment..." While the Wall Street Journal is simply calling Oracle...Chaikin Analytics | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
